These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22856387)

  • 1. Pharmacokinetic characterization of the novel TAZ modulator TM-25659 using a multicompartment kinetic model in rats and a possibility of its drug-drug interactions in humans.
    Lee KR; Choi SH; Song JS; Kwak EY; Chae YJ; Im SH; Lee BH; Seo H; Cho WK; Kim MS; Kim NJ; Ahn SH; Bae MA
    Xenobiotica; 2013 Feb; 43(2):193-200. PubMed ID: 22856387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transport characteristics and transporter-based drug-drug interactions of TM-25659, a novel TAZ modulator.
    Choi MK; Kwon M; Ahn JH; Kim NJ; Bae MA; Song IS
    Biopharm Drug Dispos; 2014 Apr; 35(3):183-94. PubMed ID: 24285344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2'-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry.
    Choi SH; Lee KR; Woo JC; Kim NJ; Moon DC; Hwang ES; Ahn SH; Bae MA; Kim MS
    J Pharm Biomed Anal; 2012 Apr; 63():47-52. PubMed ID: 22357285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
    Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
    Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
    Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey.
    Musick TJ; Gohdes M; Duffy A; Erickson DA; Krieter PA
    Drug Metab Dispos; 2008 Feb; 36(2):241-51. PubMed ID: 17991767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats.
    Lee KR; Jeong JW; Hyun HC; Jang E; Ahn S; Choi S; Joo SH; Kim S; Koo TS
    Xenobiotica; 2018 Aug; 48(8):831-838. PubMed ID: 28803538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
    Obach RS
    Drug Metab Dispos; 2000 Sep; 28(9):1069-76. PubMed ID: 10950851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
    Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
    Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats.
    Kim TH; Jeong JW; Song JH; Lee KR; Ahn S; Ahn SH; Kim S; Koo TS
    Arch Pharm Res; 2015 Nov; 38(11):2076-82. PubMed ID: 25956695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats.
    Jeong DW; Kim YH; Kim HH; Ji HY; Yoo SD; Choi WR; Lee SM; Han CK; Lee HS
    Biopharm Drug Dispos; 2007 Mar; 28(2):51-7. PubMed ID: 17163409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine.
    Bymaster FP; Chao P; Schulze H; Tran PV; Marshall RD
    Drug Metab Lett; 2013 Mar; 7(1):23-33. PubMed ID: 23826879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats.
    Lee KR; Chae YJ; Koo TS
    Xenobiotica; 2011 Dec; 41(12):1100-7. PubMed ID: 21838595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.
    Dockens RC; Santone KS; Mitroka JG; Morrison RA; Jemal M; Greene DS; Barbhaiya RH
    Drug Metab Dispos; 2000 Aug; 28(8):973-80. PubMed ID: 10901709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.